Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma
Atkins, Michael B., Rini, Brian I., Motzer, Robert J., Powles, Thomas, McDermott, David F., Suarez, Cristina, Bracarda, Sergio, Stadler, Walter M, Donskov, Frede, Gurney, Howard, Oudard, Stephane, UemЖурнал:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-19-2838
Date:
March, 2020
Файл:
PDF, 684 KB
2020
File converter
Більше результатів пошуку
More benefits 
